Maze Therapeutics, Inc./$MAZE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Maze Therapeutics, Inc.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Ticker
$MAZE
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
125
ISIN
US5787841007
Website
MAZE Metrics
BasicAdvanced
$685M
46.62
$0.34
-
-
Price and volume
Market cap
$685M
52-week high
$15.79
52-week low
$6.71
Average daily volume
117K
Financial strength
Current ratio
16.099
Quick ratio
15.812
Long term debt to equity
7.241
Total debt to equity
8.841
Profitability
EBITDA (TTM)
53.23
Gross margin (TTM)
100.00%
Net profit margin (TTM)
31.01%
Operating margin (TTM)
29.97%
Effective tax rate (TTM)
2.21%
Revenue per employee (TTM)
$1,340,000
Management effectiveness
Return on equity (TTM)
34.38%
Valuation
Price to earnings (TTM)
46.623
Price to revenue (TTM)
0.837
Price to book
2.35
Price to tangible book (TTM)
2.35
Price to free cash flow (TTM)
2.042
Free cash flow yield (TTM)
48.98%
Free cash flow per share (TTM)
766.06%
Growth
Earnings per share change (TTM)
-100.71%
Bulls say / Bears say
Maze Therapeutics successfully completed an upsized IPO in February 2025, raising approximately $140 million, providing substantial capital to advance its clinical programs. (Maze Therapeutics Press Release)
The company reported positive Phase 1 results for MZE829 in October 2024, demonstrating good tolerability and supporting once-daily dosing, which could enhance patient compliance. (GlobeNewswire)
Analysts from JPMorgan Chase & Co. initiated coverage on Maze Therapeutics with an 'overweight' rating and a $30.00 price target, indicating strong confidence in the company's growth potential. (American Banking and Market News)
Despite the successful IPO, Maze Therapeutics reported a net loss in Q4 2024, reflecting ongoing financial challenges common in clinical-stage biopharmaceutical companies. (GlobeNewswire)
The company's lead programs, MZE829 and MZE782, are still in early clinical stages, and any delays or failures in these trials could negatively impact investor confidence. (GlobeNewswire)
Maze Therapeutics operates in a highly competitive biopharmaceutical sector, facing potential challenges from larger, more established companies with greater resources. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
MAZE News
AllArticlesVideos
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
GlobeNewsWire·12 hours ago
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
GlobeNewsWire·1 month ago
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Maze Therapeutics, Inc. stock?
Maze Therapeutics, Inc. (MAZE) has a market cap of $685M as of July 11, 2025.
What is the P/E ratio for Maze Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Maze Therapeutics, Inc. (MAZE) stock is 46.62 as of July 11, 2025.
Does Maze Therapeutics, Inc. stock pay dividends?
No, Maze Therapeutics, Inc. (MAZE) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Maze Therapeutics, Inc. dividend payment date?
Maze Therapeutics, Inc. (MAZE) stock does not pay dividends to its shareholders.
What is the beta indicator for Maze Therapeutics, Inc.?
Maze Therapeutics, Inc. (MAZE) does not currently have a Beta indicator.